Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Terminated 2

Sponsor Class

NIH 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 2

Conditions

Breast Neoplasms 285Lymphoma 201Lymphoma, Large B-Cell, Diffuse 167Sarcoma 141Precursor Cell Lymphoblastic Leukemia-Lymphoma 109Hodgkin Disease 85Lymphoma, Non-Hodgkin 78Burkitt Lymphoma 67Lymphoma, Follicular 61Leukemia 58Ovarian Neoplasms 50Neoplasms 50Triple Negative Breast Neoplasms 49Lymphoma, Mantle-Cell 48Multiple Myeloma 47Neuroblastoma 44Carcinoma, Hepatocellular 44Neoplasm Metastasis 41Lymphoma, B-Cell 33Lymphoma, Large-Cell, Anaplastic 31Lymphoma, T-Cell, Peripheral 27Recurrence 26Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 25Osteosarcoma 25Liposarcoma 25Leiomyosarcoma 25Urinary Bladder Neoplasms 23Lymphoma, Large-Cell, Immunoblastic 23Liver Neoplasms 22Endometrial Neoplasms 21

Interventions

Cyclophosphamide 13fludarabine 8fludarabine phosphate 7Busulfan 5Bendamustine Hydrochloride 5Tacrolimus 4Rituximab 4Mycophenolic Acid 4ibrutinib 3Melphalan 3Bortezomib 3tetulomab tetraxetan lu-177 2ponatinib 2pembrolizumab 2cobomarsen 2Whole-Body Irradiation 2Vorinostat 2Vincristine 2Prednisone 2Peripheral Blood Stem Cell Transplantation 2Patient Reported Outcome Measures 2Mesna 2Lutetium 2Etoposide 2Doxorubicin 2Brentuximab Vedotin 2AP 1903 reagent 2thymoglobulin 1palbociclib 1ibritumomab tiuxetan 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × Immune System Diseases × Doxorubicin × Clear all
NCT02855359 2019-03-11

Denintuzumab Mafodotin (SGN-CD19A) Combined With RCHOP or RCHP Versus RCHOP Alone in Diffuse Large B-Cell Lymphoma or Follicular Lymphoma

Seagen Inc.

Phase 2 Terminated
24 enrolled 10 charts
Lymphoid

Hematologic Diseases, Immune System Diseases, Immunoproliferative Disorders, Lymphatic Diseases, Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Neoplasms, Neoplasms by Histologic Type, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse

NCT00365274 2014-06-02

SGN-30 and Combination Chemotherapy in Treating Patients With Newly Diagnosed Anaplastic Large Cell Lymphoma

National Cancer Institute (NCI)

Phase 2 Terminated
6 enrolled 3 charts
Lymphoid

Immune System Diseases, Immunoproliferative Disorders, Lymphatic Diseases, Lymphoma, Lymphoma, Non-Hodgkin, Lymphoproliferative Disorders, Neoplasms, Neoplasms by Histologic Type, Lymphoma, B-Cell, Lymphoma, T-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Large-Cell, Anaplastic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡